Table Graph
      published meta-analysis   sensitivity analysis   studies

remdesivir in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsGS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] 0.65[0.21; 2.01]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable deathsdetailed resultsGS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] 0.64[0.21; 1.98]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%796moderatenot evaluable deaths (time to event analysis only)detailed resultsGS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] 0.64[0.21; 1.98]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%796moderatenot evaluable clinical improvementdetailed resultsGS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] 1.38[0.98; 1.95]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020230%796moderatenot evaluable clinical improvement (14-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] 1.57[1.15; 2.16]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable clinical improvement (28-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] 1.81[1.19; 2.76]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable clinical improvement (7-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09] 1.20[0.88; 1.63]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020217%784moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsGS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44] GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42] 1.15[0.99; 1.34]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%796moderatenot evaluable mechanical ventilationdetailed resultsGS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30] GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45] 0.20[0.03; 1.16]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable recoverydetailed resultsGS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37] GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45] 1.15[0.99; 1.33]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%796moderatenot evaluable serious adverse eventsdetailed resultsGS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23] GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14] 0.53[0.30; 0.94]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%784moderatenot evaluable adverse eventsdetailed resultsGS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42] GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80] 1.40[1.05; 1.87]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202024%784moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-01 01:37 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 510 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons